Poster Spotlight Session 15: Novel Nuclear Receptor Targeting Therapies
Thursday, December 7 • 5:30 p.m. ­­– 6:30 p.m. • Stars at Night Ballroom 1-2

Presentation: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Palbociclib in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase 1b Cohort

Erika Hamilton, MD
Director, Breast Cancer Research, Sarah Cannon Research Institute
Nashville, Tennessee

What is your presentation about?
This abstract outlines the activity of ARV-471, an oral PROTAC degrader, in combination with a CDK4/6 inhibitor in patients with HR+ metastatic breast cancer with a median of three prior therapies in the metastatic setting and boasts impressive CBR and ORR in this setting.

What makes this topic important in 2023?
Novel endocrine agents are needed in the post-CDK4/6 world. Whereas much has been discussed regarding novel oral SERDs, this combination with a PROTAC ER degrader and CDK4/6 represents a different flavor of novel endocrine therapy and could be used in second line post AI and CDK4/6 or in first line.

How did you get involved in this particular area of breast cancer research, care, or advocacy?
Novel agents for those facing incurable metastatic cancer remains an unmet medical need. Advancing therapeutic options for patients through clinical trials is a passion of mine to ultimately advance care for all patients in the future.